NCT03280394Recruiting
Liquid Biopsy in Mature B-cell Tumors
Summary
The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.
Inclusion criteria
• Male or female adults 18 years or older • Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria • Willing and able to comply with scheduled study procedures • Evidence of a signed informed consent
Exclusion criteria
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- Oncology Institute of Southern Switzerland(Other)
- Protocol no.
- IOSI-EMA003
- Conditions
- Mature B-Cell Neoplasm
- Interventions
- Diagnostic test
Treatments studied
- Liquid Biopsy
Locations · 1
- Bellinzona, SwitzerlandInstitute of Oncology ResearchRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: July 9, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.